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http://dx.doi.org/10.1016/j.ccr.2013.12.007SUMMARYCoactivator-associated arginine methyltransferase 1 (CARM1), a coactivator for various cancer-relevant
transcription factors, is overexpressed in breast cancer. To elucidate the functions of CARM1 in tumorigen-
esis, we knocked out CARM1 from several breast cancer cell lines using Zinc-Finger Nuclease technology,
which resulted in drastic phenotypic and biochemical changes. The CARM1 KO cell lines enabled identifica-
tion of CARM1 substrates, notably the SWI/SNF core subunit BAF155. Methylation of BAF155 at R1064 was
found to be an independent prognostic biomarker for cancer recurrence and to regulate breast cancer cell
migration and metastasis. Furthermore, CARM1-mediated BAF155 methylation affects gene expression by
directing methylated BAF155 to unique chromatin regions (e.g., c-Myc pathway genes). Collectively, our
studies uncover a mechanism by which BAF155 acquires tumorigenic functions via arginine methylation.INTRODUCTION
Coactivator-associated arginine methyltransferase 1 (CARM1),
also known as PRMT4, is a type I protein argininemethyltransfer-
ase (PRMT) that asymmetrically dimethylates protein substrates
on arginine residues. CARM1 was originally identified as a coac-
tivator for steroid hormone receptors (Chen et al., 1999). CARM1
knockout (KO) mice die at birth (Yadav et al., 2003), showing
that CARM1 is specifically required for postnatal survival. Inter-
estingly, methyltranserase-inactivated CARM1 knockin mice
phenocopy CARM1 null mice, indicating that CARM1 requiresSignificance
Although mutations or epigenetic changes inactivating and al
SNF are frequently linked to cancer, the mechanisms underlyin
and pathways that induce SWI/SNF’s oncogenic effects would
driving changes while retaining SWI/SNF’s normal functions. H
strate for arginine methyltransferase CARM1. Methylation of B
drive regulation of genes in the c-Myc and certainmetastatic pa
remodeling factor is activated by arginine methylation to reguits enzymatic activity for the majority, if not all, of its in vivo func-
tions (Kim et al., 2010).
Emerging evidence implies oncogenic functions of CARM1 in
human cancer. CARM1 transactivates many cancer-associated
transcription factors including NF-kB, p53, E2F1, and steroid
receptors such as estrogen receptor alpha (ERa; Bedford and
Clarke, 2009), and promotes cancer cell proliferation (El Mes-
saoudi et al., 2006; Frietze et al., 2008). Recent tissue microarray
studies revealed that CARM1 expression is higher in metastatic
breast tumors than in normal breast tissues (Mann et al., 2013),
particularly in triple negative tumors lacking expression of ERa,tering the functions of chromatin remodeling complex SWI/
g these connections remain unclear. Delineating the factors
enable preventive and therapeutic targeting of these cancer-
ere, we identify BAF155, a SWI/SNF core subunit, as a sub-
AF155 is required for its association with genomic sites that
thways. This represents amechanismbywhich a chromatin-
late genes that enhance tumor progression and metastasis.
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Figure 1. Generation of CARM1 KO Breast Cancer Cell Lines
(A) Western blot analysis of CARM1 and methyl-PABP1 using whole cell lysates from CARM1+/+ MEF, CARM1/ MEF, MCF7, and MCF7-shCARM1 cells.
b-Actin was used as a loading control.
(B) Targeting exon 8 of human CARM1 by ZFN.
(C) Western blot of CARM1, PABP1, methyl-PABP1, PRMT5 in parental and CARM1 KO MCF7, MDA-MB-231, and HEK293T cells.
(D) Genomic DNA sequence of ZFN targeting site in MCF7 CARM1 KO and MDA-MB-231 CARM1 KO cell clones.
(E) ZFN-mediated KO frequency of CARM1 in each indicated cell line.
(legend continued on next page)
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altered CARM1expression may underlie pathological conditions
and that, in breast cancer, CARM1 has roles beyond serving as a
coactivator for ERa. It remains to be determined whether the
oncogenic functions of CARM1 depend on its ability to regulate
cancer-driving transcription factors or to directly methylate can-
cer-relevant substrates, or both.
The significance of identifying cancer-relevant CARM1 sub-
strates is underscored by studies of the roles of histone H3
methylation in transcriptional activation of ER target genes (Wu
and Xu, 2012). Nonhistone substrates include p300/CBP,
AIB1/SRC-3, and RNA binding proteins such as PABP1, HuR,
HuD, and HnRNPs (Bedford and Clarke, 2009). Multiple lines of
evidence indicate that normal CARM1 expression is well above
that required for its essential roles. For instance, normal develop-
mental functions were maintained in genetically engineered
CARM1 hypomorphic mice with only 25% of the wild-type
(WT) CARM1 level (Kim et al., 2010). We recently showed that
knocking down 90% of endogenous CARM1 in MCF7 cells
only slightly reduces methylation of PABP1 (Zeng et al., 2013).
These results imply that even greatly depleted CARM1 catalytic
activity and substrate methylation are sufficient to maintain
major biological functions. Previously, CARM1 null mouse em-
bryonic fibroblast cell lysates were used as a hypomethylated
substrate source that led to identifying PABP1 as a CARM1 sub-
strate (Lee and Bedford, 2002). The CARM1 null cancer cell lines
would greatly facilitate identifying cancer-relevant substrates
and understanding of CARM1 oncogenic functions in breast
cancer cells. Herein, we generated CARM1 KO cancer cell lines
and used them to explore the roles of BAF155 methylation by
CARM1 in breast cancer models.
RESULTS
Generation of CARM1 KO Breast Cancer Cell Lines
Using ZFN Technology
We recently developed a sensitive methylated PABP1 (me-
PABP1) western blot method to monitor endogenous CARM1
levels and activity (Zeng et al., 2013). In contrast to the complete
loss of me-PABP1 in CARM1 null mouse embryonic fibroblasts
(CARM1/ MEFs; Figure 1A, lanes 1 and 2), we found that
even though small hairpin RNA (shRNA)-mediated knockdown
decreased CARM1 levels by 90%, the cellular me-PABP1 level
decreased by less than 20% (Figure 1A, lanes 3 and 4). Thus,
low levels of CARM1 are capable of substantial PABP1 methyl-
ation. Because CARM1 substrates therefore should remain
significantly methylated in CARM1 knockdown cells but be hy-
pomethylated in CARM1 null cells, we generated CARM1 null
cancer cell lines to identify cancer-relevant CARM1 substrates.
We utilized Zinc Finger Nuclease (ZFN) technology to create a
highly specific genomic scissors targeting exon 8 of CARM1
(Figure 1B), and through this generated a complete KO in cancer
cell lines. After transient transfection of ZFN plasmids into cells,
we performed limiting dilution to select single clones and(F) Western blot of CARM1, PABP1, and me-PABP1 in MCF7, two MCF7 CA
retroviral infection.
(G) Representative cell morphology images of MCF7 cells, MCF7-shCARM1 cell
See also Figure S1.confirmed CARM1 KO by loss of me-PABP1 (Figure 1C) and
genomic DNA sequencing (Figure 1D). Representative KO
clones with complete depletion of me-PABP1 are shown in Fig-
ure 1C for MCF7, MDA-MB-231, and human embryonic kidney
293T (HEK293T) cell lines. The human CARM1 gene locus
resides at chromosome19 p13.2, a region triplicated in MCF7
and duplicated in MDA-MB-231 cells. The genomic DNA
sequencing analysis of two representative CARM1 KO clones
of MCF7 and MDA-MB-231 (Figure 1D) revealed misrepaired
DNA, resulting in mRNA degradation and gene deletion.
Although the efficiency of ZFN KO varied among cell lines
at 1.3%, 0.5%, and 3.6% for MCF7, MDA-MB-231, and
HEK293T, respectively, the average KO efficiency across all
clones analyzed was 1.2% (Figure 1E). When CARM1was re-ex-
pressed in two individual MCF7 CARM1 KO clones, me-PABP1
was restored (Figure 1F). Interestingly, we found that KO of
CARM1 in MCF7 cells inducedmorphology changes (Figure 1G),
whereas nomorphology changewas observed inMCF7 cells ex-
pressing CARM1 shRNA to knock down CARM1 to 10% of WT
levels (Figure 1G). The morphology change in the two KO clones
was rescued by re-expressingWTCARM1 (Figure 1G) but not an
enzyme-defective mutant (data not shown). We compared the
in vitro cell growth and in vivo tumor growth of MDA-MB-231
CARM1 KO and MCF7 CARM1 KO with their parental cells. KO
of CARM1 impeded cell growth and colony formation (Figures
S1A and S1B available online) and tumor growth in vivo (Fig-
ure S1C). These data strongly suggest that the cell morphology
change and growth defect in KO cells could be due to loss of
methylation of CARM1 substrates.
Identification of BAF155 as a Substrate for CARM1
The lack of understanding of the biological functions of CARM1
in cancers is at least partially attributed to the limited number of
known CARM1 substrates. A few CARM1 substrates were previ-
ously identified or validated by comparing CARM1+/+ and
CARM1/ MEF cell lysates for in vitro and in vivo methylation
(Cheng et al., 2007; Kim et al., 2004). In contrast to CARM1-
expressing cells, where potential CARM1 substrates would be
blocked for further methylation, CARM1/ MEF lysates served
as a hypomethylated substrate resource for CARM1 substrate
identification. Indeed, we found that MCF7 CARM1 KO cell
lysates were more strongly methylated in vitro by recombinant
CARM1 protein than CARM1/ MEF cell lysates, as assayed
by 3H-CH3 labeling in an autoradiograph (Figure S2A) and west-
ern blotting using a newly developed asymmetrically dimethy-
lated arginine (a-ADMA) antibody (Dhar et al., 2013; Figure S2B).
This result implies that MCF7 CARM1 KO cells serve as a good
resource for substrate discovery.
When cell lysates derived from parental MCF7 cells and
CARM1 KO cells were probed with monomethylated arginine
(a-MMA) and a-ADMA antibodies in western blots, asymmetri-
cally dimethylated proteins, in particular those in the high mo-
lecular weight range, were significantly affected by CARM1
KO (Figure 2A). This is in contrast to the lack of a significantRM1 KO clones, and MCF7 CARM1 KO clones re-expressing CARM1 by
s, and the MCF7-derived CARM1 KO cell lines listed in (F). Scale bar = 40 mm.
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Figure 2. Identification of BAF155 as a Substrate for CARM1
(A) Western blot analysis of total proteins in MCF7 and MCF7 CARM1 KO cells using antibodies against MMA and ADMA moieties.
(B) Coomassie brilliant blue staining of proteins immunoprecipitated with anti-ADMA antibody from total cell lysates of MCF7 and MCF7 CARM1 KO cells.
Discrete bands in the high molecular weight range were excised and subjected to mass spectrometry analysis, from which ten candidate proteins were identified
(right panel).
(C) Western blot analysis of input and anti-ADMA immunoprecipitated proteins using antibodies to detect endogenous BRG1, BAF170, BAF155, and BAF250, or
against the FLAG epitope to detect transfected, FLAG-tagged TRAP150, Caprin1, TRAP230, and BCLAF1 in HEK293T and HEK293T CARM1 KO cells.
(D) Coomassie brilliant blue staining (left panel) and autoradiograph (right panel) of in vitro methylated BAF155 by CARM1 in the presence of 3H-SAM.
(E) Western blot analysis of anti-BAF155 immunoprecipitated proteins using anti-ADMA, BAF155, and CARM1 antibodies in HEK293T CARM1 KO cells before
and after restoration with WT CARM1 or a methylation-defective CARM1 mutant (MUT).
See also Figure S2.
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substrates in breast cancer cells, we used the a-ADMA anti-
body to immunoprecipitate proteins from cell lysates derived24 Cancer Cell 25, 21–36, January 13, 2014 ª2014 Elsevier Inc.from parental MCF7 cells expressing WT CARM1 and MCF7
CARM1 KO cells, respectively. The discrete bands in WT cells
stained with Coomassie blue were excised and subjected to
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identified (Figure 2B). To discern whether these proteins are
CARM1 substrates, we immunoprecipitated endogenous pro-
teins (BRG1, BAF170, BAF155, and BAF250) or FLAG-tagged
proteins (TRAP150, Caprin 1, TRAP230, and BCLAF1) tran-
siently transfected to MCF7 WT or KO cells, and followed
their fate in western blots using a-ADMA or a-FLAG antibody,
respectively.
Western blot results using a-ADMA antibody (Figure 2C)
classified the candidate proteins into three categories. The first
category includes BAF155 and TRAP230 proteins, which are
dimethylated in WT but not in KO MCF7 cells, indicating that
arginine dimethylation of these proteins is CARM1 dependent.
The second category includes Caprin1 and BCLAF1 proteins,
which are dimethylated in WT and KO cells at similar levels,
indicating that CARM1 is not their sole methyltransferase.
Finally, the third category includes BAF170, BRG1, BAF250,
and TRAP150 proteins, which are not recognized by a-ADMA
antibody, suggesting that they were immunoprecipitated by
the a-ADMA antibody via indirect association with bone fide
CARM1 substrates (e.g., BRG1, BAF250, and BAF170 are in
complex with methylated BAF155). Although the a-ADMA anti-
body recently developed by Cell Signaling appeared sensitive
in detecting CARM1 substrates, this antibody has not been
extensively characterized (Dhar et al., 2013).
Since a previous study had reported that a histone H3 argi-
nine17 dimethylation (H3R17me2) antibody, while recognizing
the H3R17me2 mark, also recognized other CARM1 substrates
in MEF cells (Cheng et al., 2007), we employed this anti-
H3R17me2 antibody for western blotting (Figure S2C, left panel)
and immunoprecipitation, followed by Coomassie blue staining
(Figure S2C, right panel), using total cell lysates from MCF7
WT and KO cells. Similar to the pattern detected by a-ADMA
antibody, the recognized proteins specific to CARM1 WT but
not CARM1 KO cells reside in the high molecular weight range,
among which BAF155 was identified using mass spectrometry
(Figure S2C). Correspondingly, one strong band (Figure S2D,
arrow head) migrating between 130 and 250 kDa was detected
by a-ADMA antibody in the a-H3R17me2 immunoprecipitates
from WT but not KO MCF7 cell lysates. This band was subse-
quently proved to be BAF155 by reciprocal immunoprecipitation
using H3R17me2 and BAF155 antibodies (Figures S2E and S2F).
Collectively, BAF155 appeared to be amain substrate of CARM1
in MCF7 cells detected by both a-ADMA and H3R17me2
antibodies.
To address whether BAF155 ismethylated by CARM1 directly,
we performed in vitro methylation assays using recombinant
CARM1 and hypomethylated BAF155 purified from HEK293T
CARM1 KO cells in the presence of adenosyl-L-methionine,
S-[methyl-3H] (3H-SAM). As expected, BAF155 was methylated
by CARM1 in vitro (Figure 2D). Finally, we demonstrated that
BAF155 methylation could be restored in HEK293T CARM1
KO cells by expressing WT CARM1 but not a methylation-
defective mutant (Figure 2E). These results collectively
demonstrate that CARM1 is both necessary and sufficient to
methylate BAF155. In keeping with this finding, CARM1 was
found to be the only PRMT among PRMT family members
(PRMT1–PRMT8) that is capable of methylating BAF155
in vitro (Figure S2G).CARM1 Methylates BAF155 at a Single Site, R1064
Although multiple CARM1 substrates were discovered using the
a-ADMA antibody and CARM1 KO cell line (Figure 2B), we chose
to focus on BAF155 because BAF155, a core subunit of switch/
sucrose nonfermentable (SWI/SNF) chromatin remodeling com-
plex, has been reported upregulated in colon, cervical, and pros-
tate cancer (Lapointe et al., 2004; Tomlins et al., 2007; Varambally
et al., 2005). Using PMeS (Shi et al., 2012), an online tool for pre-
dicting protein methylation sites based on an enhanced feature-
encoding scheme, five putative arginine methylation sites were
predicted on human BAF155 (Table S1). Based on the putative
methylation sites, a full-length and four C-terminally truncated
BAF155 derivatives with C-terminal myc tags were constructed
(Figure 3A). These plasmids were transiently transfected into
HEK293T cells, and the resulting proteins were immunopreci-
pated using a-myc antibody and western blotted with a-ADMA
antibody (Figure 3B). Notably, full-length BAF155 but none
of the truncated BAF155 proteins was detected by a-ADMA
antibody, suggesting that the BAF155 methylation site follows
residue 956. We then individually mutated C-proximal R1032
and R1064 to lysine in FLAG-tagged expression plasmids.
After transient expression and anti-FLAG immunoprecipitation,
FLAG-BAF155R1032K but not FLAG-BAF155R1064K protein was
detected by a-ADMA antibody in vivo (Figure 3C). Similarly, the
recombinant BAF155R1064K mutant protein was not methylated
by recombinant CARM1 in vitro (Figure 3D). Thus, R1064 is the
only BAF155 site methylated by CARM1.
Antibodies against endogenous CARM1 or BAF155 each
immunoprecipitated both proteins from MCF7 cell lysates
(Figure 3E), suggesting that CARM1 and BAF155 may directly
interact. To map the BAF155 region mediating association with
CARM1, we linked each of a series of BAF155 truncation deriv-
atives (Chen and Archer, 2005) with a T7 promoter and FLAG
tag (Figure 3F) for in vitro transcription/translation assays. As
shown in Figure 3F, full-length BAF155 and its C-terminally trun-
cated (D1, D2, D3 and D4) but not N-terminally truncated (D5, D6
and D7) derivatives bound strongly to bacterially expressed
glutathione S-transferase CARM1 (GST-CARM1). Thus, the
acidic domain at the BAF155 N terminus mediates interaction
with CARM1, although R1064, the site of methylation, localizes
to the BAF155 C terminus. R1064 of human BAF155, located
in the evolutionarily conserved proline- and glutamine-rich (P/
Q-rich) domain, is conserved among higher eukaryotes (Fig-
ure 3G). BAF170, while sharing 61.7% protein sequence identity
with BAF155, lacks an arginine residue at a position equivalent
to R1064 in its corresponding P/Q-rich domain (Figure 3H).
This explains why BAF170, a close homolog of BAF155, is not
a substrate for CARM1 (Figure 2C).
The Majority of Endogenous BAF155 in MCF7 Cells Is
Dimethylated
To investigate the prevalence of endogenous BAF155 dimethy-
lation in breast cancer cells, we generated a rabbit polyclonal
antibody specific for dimethylated BAF155 (Figure S3A). This
me-BAF155 antibody detects methylation of endogenous
BAF155 in WT MCF7 cells but not in two MCF7 CARM1 KO
clones (Figure S3B). Similar to PABP1 (Figure 1A), me-BAF155
was still detectable in MCF7-shCARM1 cells (Figure S3C). To
determine the percentage of endogenous BAF155 methylatedCancer Cell 25, 21–36, January 13, 2014 ª2014 Elsevier Inc. 25
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BAF155 using theme-BAF155 antibody and performed quantita-
tive western blotting of equal portions of the input and flow-
through fractions using the total BAF155 antibody (Figure S3D).
Quantitation of the band intensities across three independent ex-
periments revealed that 74% of endogenous BAF155 was
methylated by CARM1 in MCF7 cells. Moreover, BAF155 and
me-BAF155 immunofluorescence were confined to the nucleus
(Figure S3E). Since the majority of endogenous BAF155 is dime-
thylated, we went on to study the role of BAF155 methylation in
human breast cancer cells.
BAF155 Methylation at R1064 Creates Unique
Chromatin Association Patterns
BAF155, a core component of the SWI/SNF chromatin remodel-
ing complex, was shown to associate with chromatin depen-
dently or independently of other SWI/SNF subunits using
chromatin immunoprecipitation sequencing (ChIP-seq) in HeLa
cells (Euskirchen et al., 2011). Accordingly, we decided to deter-
mine the effect of BAF155 methylation on its chromatin associa-
tion. First, to substitute endogenous BAF155 with BAF155R1064K
mutant, we infected MCF7 cells with retrovirus vectors express-
ing either WT BAF155 (BAF155WT), mutant BAF155R1064K, or
GFP as a negative control (Figure 4A). After confirming that
the resulting total BAF155 level was twice the endogenous
BAF155 level, we stably knocked down endogenous BAF155 us-
ing a lentiviral-expressing shRNA, which selectively targets the
30UTR of the endogenous, but not the lentiviral-expressed,
BAF155 mRNA. Figure 4A shows that BAF155 was silenced
in MCF7-GFP cells, and that MCF7-BAF155WT and MCF7-
BAF155R1064K cells express reconstituted BAF155WT and
BAF155R1064K proteins to levels similar to that of endogenous
BAF155 protein in the parental MCF7 cells. Interestingly,
substituting endogenous BAF155 with BAF155R1064K, like
BAF155 knockdown, significantly reduced colony size (Fig-
ure 4B, lower panels) and yield (Figure 4C), while cell morphology
was not changed (Figure 4B, upper panels). To investigate
whether BAF155 methylation by CARM1 is required for
CARM1-induced colony formation in MCF7 cells, we first stably
overexpressed BAF155WT and BAF155R1064 in MCF7 CARM1
KO cells, respectively, followed by knocking down the endo-
genous BAF155 in these cells using lentivirus-expressing
shBAF155. Subsequently CARM1 was restored in MCF7Figure 3. CARM1 Methylates BAF155 at a Single Site, R1064
(A) Schematic diagram of BAF155 full-length cDNA and C-terminally truncated der
cassette fused to its C terminus. Red arrows point to putative arginine methylati
(B) Plasmids expressing the BAF155 cDNA derivatives shown in (A) were transient
antibody (upper panel). Total cell lysates were immunoprecipitated with anti-Myc
(C) FLAG-tagged recombinant BAF155WT, BAF155R1032K, and BAF155R1064K pro
and detected by western blotting using anti-FLAG (left panel) or anti-ADMA (righ
(D) In vitro assay using recombinant CARM1 and 3H-SAM to test for methylatio
KO cells.
(E) Reciprocal coimmunoprecipitation of CARM1 with BAF155, and BAF155 with
(F) Mapping of CARM1-interacting domain to the N-terminal acidic domain of BAF
tagged BAF155 truncation derivatives that were incubated with GST-CARM1 pr
tates were tested for the presence of GST-CARM1 by western blotting using ant
(G) CLUSTALW alignment of vertebral BAF155 sequences flanking human BAF1
(H) CLUSTALW alignment of P/Q-rich domain sequences of BAF155 (with R1064
See also Figure S3 and Table S1.CARM1 KO cells expressing either BAF155WT or BAF155R1064,
and colony formation assays were performed. The expected
levels of total BAF155, me-BAF155, and CARM1 proteins were
confirmed by western blotting (Figure 4D). Restoring CARM1 in
BAF155WT-expressing but not BAF155R1064K-expressing cells
rescued colony formation in terms of both colony size and yield
(Figures 4E and 4F). These results further support that BAF155
methylation affects the cellular functions of BAF155.
To ensure that BAF155 methylation does not affect its assem-
bly into the SWI/SNF complex, we expressed BAF155WT and
BAF155R1064K in SKOV3, an ovarian cancer cell line that ex-
presses all SWI/SNF components except BAF155 (DelBove
et al., 2011). As shown in Figure S4, immunoprecipitating
either BAF155WT or BAF155R1064K effectively pulled down other
SWI/SNF components such as BRG1, BAF60a, and BAF47
in SKOV3 cells. Only BAF155WT, but not BAF155R1064K, was
methylated by endogenous CARM1, as revealed by a-ADMA
immunoblot (Figure S4A). Thus, both CARM1-methylated
and -unmethylated BAF155 assemble into SWI/SNF complexes.
Next we determinedwhethermethylation of BAF155 affects its
chromatin association, using a genomic ChIP-seq approachwith
MCF7-BAF155WT and MCF7-BAF155R1064K cells. A ChIP-grade
BAF155 antibody (Euskirchen et al., 2011) was used for ChIP fol-
lowed by Illumina high-throughput sequencing. Representative
BAF155WT, BAF155R1064K, and BRG1 binding sites in HeLa
and MCF7 cells in a 7.5 Mb region of chromosome 8 are shown
in Figure 4G. As expected, while some BAF155WT peaks identi-
fied in MCF7 cells overlap with the binding sites of BAF155 and
BRG1 in HeLa cells (Figure 4G, box a; Euskirchen et al., 2011),
BAF155WT also has unique binding sites in MCF7 and HeLa cells
(Figure 4G, box d). We subsequently analyzed the genome-wide
distribution of BAF155 binding peaks in MCF7 expressing WT or
mutant BAF155. Totals of 2,667 and 1,566 peaks were identified
for BAF155WT or BAF155R1064K, respectively. Among these, 983
peaks overlapped (Table S2). The numbers of annotated genes
in the genomic regions associated with these BAF155WT and
BAF155R1064K binding sites are shown in Figure 4H. As in HeLa
cells, approximately 60% of BAF155 binding sites in MCF7 cells
reside in gene bodies (exons and introns; Figure 4I). Moreover,
BAF155 peaks in MCF7 cells are enriched within +50 kb from
the transcription starting sites (TSSs), which are likely to contain
enhancer regions (Figure 4J). This pattern is consistent with
those of BAF155 and BRG1, SNF5/BAF47 in HeLa cells, but itivatives, each with a nuclear localization sequence/Myc (NLS-Myc) epitope tag
on sites predicted by the PMeS program.
ly transfected into HEK293 cells and detected bywestern blotting with anti-Myc
antibody and western blotted with anti-ADMA antibody (lower panel).
teins were immunoprecipitated from HEK293T cells with anti-FLAG antibody
t panel) antibodies.
n of BAF155WT and BAF155R1064K proteins prepared from HEK293T CARM1
CARM1, from MCF7 cell lysates.
155 by GST-pull-down assay. Left panel shows schematic diagrams of FLAG-
oteins and immunoprecipitated with anti-FLAG antibody. The immunoprecipi-
i-GST antibody (right panel).
55 methylation site R1064, which is highlighted in red.
highlighted in red) and its homolog BAF170 protein.
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Figure 4. BAF155 Methylation Promotes MCF7 Cell Colony Formation and Directs Unique Genomic Association Patterns
(A) Western blotting of BAF155 and me-BAF155 in MCF7 cells and MCF7-shBAF155 cells restored with GFP, BAF155WT, or BAF155R1064K.
(B) Representative images of cell morphology (upper panel; scale bars = 40 mm) and colonies (lower panel; scale bars = 100 mm) for parental MCF7 and
MCF7-shBAF155-GFP cells, and BAF155WT- and BAF155R1064K-restored MCF7 cells.
(legend continued on next page)
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BAF170, which peaks around 50 kb from TSSs (Figure 4J).
The Genomic Regions Enrichment of Annotations Tool (GREAT)
identified meiosis and c-Myc pathways as the two leading path-
ways uniquely associated with BAF155WT but not BAF155R1064K
(Figure 4K), implying that BAF155 methylation might direct its
association with genes involved in potentially cancer-relevant
c-Myc pathways.
BAF155 Methylation Controls Expression of Genes in
the c-Myc Pathway
In contrast to the promoter regions of CDH1 and TFF1 genes
where both BAF155WT and BAF155R1064K bind similarly (Fig-
ure S5A), many c-Myc pathway genes were selectively enriched
for BAF155WT but not BAF155R1064K, as shown in Figure S5B for
CDCA7, COL1A2, GADD45A, DDX18, and NDRG1 in HeLa and
MCF7 cells. Next we performed conventional ChIP using distinct
sets of biological samples to validate whether BAF155 is associ-
ated with the binding sites determined in the ChIP-seq experi-
ment. As shown in Figure 5A, BAF155WT but not BAF155R1064K
was found associated with the ChIP-seq-implicated regions
of CDCA7, COL1A2, GADD45A, DDX18, and NDRG1, whereas
both BAF155 forms were detected at the promoter region of
CDH1. ChIP using the me-BAF155 antibody confirmed the
association of me-BAF155 to COL1A2 and GADD45A genes
in MCF7-BAF155WT but not in MCF7-BAF155R1064K cells (Fig-
ure 5B). Importantly, BAF155 association strongly correlated
with gene expression. COL1A2 and GADD45A mRNA levels,
for example, were higher in MCF7-BAF155WT than in MCF7-
BAF155R1064 or MCF7-GFP with endogenous BAF155 silenced
(Figure 5C). To examine whether the association of BAF155
withCOL1A2 andGADD45A genes depends on CARM1 expres-
sion, we performed ChIP assays in parental MCF7 and CARM1
KO cells. As shown in Figures 5D and 5F, CARM1 KO resulted
in significant decreases of BAF155 association with the impli-
cated regions of COL1A2 and GADD45A. Thus, CARM1 is an
important determinant for BAF155 genomic association, and
CARM1-mediated BAF155 methylation could induce BAF155
association with unique genomic sites to control gene regulation.
Interestingly, we could not detect binding above background
of CARM1, BAF53, or SWI/SNF adenosine triphosphatase
(ATPase) subunits BRG1 and BRM at the same regions of the
COL1A2 and GADD45A genes where BAF155 binds (Figures
5E and 5G), although BRG1 could be detected at positive control(C) Colony yields for the cell lines in (B).
(D) Western blotting analysis of CARM1, BAF155, and me-BAF155 proteins in MC
BAF155R1064K cells engineered to express either GFP or CARM1. b-Actin was us
(E) Representative images of colonies formed by each cell line shown in (D). Sca
(F) Colony yields for the cell lines in (D).
(G) ChIP-seq identifies BRG1, BAF155WT, and BAF155R1064K association in an 
regions were identified inMCF7 andHeLa cells as detailed in Table S2. An ‘‘a’’ den
denotes BAF155 binding peak only found in HeLa cells; ‘‘c’’ denotes shared BAF1
BAF155WT and BAF155R1064K peaks only found in MCF7 cells; and ‘‘e’’ denotes
(H) Venn diagram showing the overlapping and discrete BAF155 cistromes in MC
genes were defined as the regions between 5.0 kb upstream and 1.0 kb downst
(I) Distribution of the genome-wide association of BAF155 binding sites in MCF7
(J) Distribution of genomic association sites of RNA pol II and SWI/SNF subunits
(K) BAF155 genomic association sites map to different signaling pathways in MC
Quantitative data are presented as averages ± SD. Student’s t test was used forregions (e.g., the CDH1 and TFF1 promoters; Figures S5C and
S5D). The positive binding of other SWI/SNF subunits SNF5,
BAF53, and BRM to CDH1 and TFF1 genes similarly validated
the corresponding antibodies for ChIP (Figure S5C). Despite
the lack of detectable binding of BRG1 to COL1A2, GADD45A,
and NDRG1 regions (Figure S5D), SNF5 but not BAF53 was
found at the BAF155-binding sites (Figures 5E, 5G, and S5D)
of the corresponding genes. Accordingly, methylated BAF155
might be in a subcomplex with other BAFs such as SNF5 at
unique chromatin sites.
BAF155 Methylation Correlates with Human Breast
Cancer Progression and Malignancy
To determine whether me-BAF155 could serve as a prognostic
biomarker for human breast cancer, we first optimized the
me-BAF155 peptide antibody for immunohistochemistry (IHC).
IHC staining of me-BAF155 could be completely blocked by
me-BAF155 peptide but not by nonmethylated BAF155 peptide
(Figure S6A), showing that the me-BAF155 antibody is specific.
We next performed IHC using total BAF155 antibody as well
as me-BAF155 antibody with four pairs of matched breast
normal and tumor samples. As shown in Figure S6B, me-
BAF155 staining was almost undetectable in normal samples,
while both total BAF155 protein level and me-BAF155 intensity
were elevated in breast tumors. Notably, CARM1 protein levels
also were elevated in tumors relative to matched normal tissues
(Figure S6C).
These results suggest that the increased level of me-
BAF155 in tumors reflects overall elevated levels of BAF155
and CARM1. Thus, the me-BAF155 level might be a sensitive
breast cancer progression biomarker. To test this hypothesis,
we employed commercial tissuemicroarrays (TMAs), which con-
tained80 samples from normal tissues, tumor-adjacent normal
(TAN), benign tumors, malignant tumors, and metastatic tumors
excised prior to treatment. Modest me-BAF155 staining was
seen with normal (Figure 6A), TAN, and benign tissues (Fig-
ure 6B). In contrast, significantly greater me-BAF155 IHC
staining was observed with malignant and metastatic tumors.
One hundred percent of metastatic tumors (6/6) showed strong
positive staining for me-BAF155 (Figures 6C and 6D). To investi-
gate if BAF155 methylation status is associated with clinical
outcomes, we employed TMAs containing 372 breast tumor
specimens with 150 months of clinical follow-up. TMAs
were immunostained with me-BAF155-specific antibody, andF7 CARM1 KO clone 1, MCF7-CARM1KO-BAF155WT, and MCF7-CARM1KO-
ed as loading control.
le bar = 100 mm.
750 kb region of chromosome 8. The coordinates shown are in hg19 and all
otes a peak that is detected by BRG1 and BAF155 in both HeLa andMCF7; ‘‘b’’
55 and BRG1 binding peaks in HeLa but not in MCF7 cells; ‘‘d’’ denotes shared
BAF155WT binding only found in MCF7 cells.
F7 cells expressing BAF155WT and BAF155R1064K. Genomic-region-associated
ream of annotated genes, using GREAT.
cells is comparable to that in HeLa cells.
relative to TSSs in HeLa (top two panels) and MCF7 cells (bottom panel).
F7-BAF155WT and MCF7-BAF155R1064K cells.
statistical analysis. **p < 0.01. See also Figure S4 and Table S2.
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and divided into me-BAF155-negative (bottom 25% intensity)
and -positive (top 75% intensity) groups. The Kaplan-Meier
plot shows that the me-BAF155-negative patients have a higher
recurrence-free survival rate than do me-BAF155-positive
patients (Figure 6E). A log-rank test performed to formally test
this difference in recurrence-free survival rates yielded a statisti-
cally significant p value of 0.0497. Notably, the results of the
multivariate analyses performed using the Cox proportional
hazards model indicate a recurrence hazard 1.789 times higher
for patients with me-BAF155-positive tumors when compared
with me-BAF155-negative tumors (p = 0.034; Figures 6F and
6G). This hazard ratio of 1.789 for me-BAF155-positive tumors
is similar to that of triple-negative breast cancer (hazard ratio =
1.845), a category well known for its poor prognosis. This differ-
ence in recurrence hazard rates is shown in the cumulative
hazard plot (Figure 6F). These data underscored the potential
use of me-BAF155 as a biomarker of malignant breast cancer
and also in prognostic stratification of breast cancer patients.
Methylation of BAF155 Promotes Migration and
Metastasis of Breast Cancer Cells In Vitro and In Vivo
To investigate of the role of BAF155 methylation in tumor migra-
tion and metastasis, we employed MDA-MB-231, an aggressive
breast cancer cell line model, for in vitro transwell migration and
in vivo metastasis studies. Using a strategy similar to that for
MCF7 cells (Figure 4A), we engineered stable cell line MDA-
MB-231-GFP with endogenous BAF155 knockdown, and its
reconstituted derivatives MDA-MB-231-BAF155WT and MDA-
MB-231-BAF155R1064K (Figure 7A). Knockdown of endogenous
BAF155 in MDA-MB-231 cells significantly decreased cell
growth (Figure 7B, compare- with,), which was rescued by
restoring BAF155WT but not BAF155R1064K (Figure 7B, compare
: with 6). Furthermore, knockdown of endogenous BAF155
in MDA-MB-231 cells significantly decreased cell migration in
transwell assay, an effect that was partially rescued by restoring
BAF155WT but not BAF155R1064K (Figure 7C). To explore the
possibility that methylation of BAF155 is required for establishing
metastatic lung colonization in vivo, we injected MDA-MB-
231-BAF155WT and MDA-MB-231-BAF155R1064K cells stably
expressing firefly luciferase intravenously to nude mice and
monitored tumor cell colonization and outgrowth in lung using
bioluminescence imaging. On the day of injection (day 0), both
WT and mutant BAF155-expressing MDA-MB-231 cells accu-Figure 5. BAF155 Methylation Controls Expression of Genes in the c-M
(A) Differential binding of BAF155 to CDCA7, COL1A2, GADD45A, DDX18, and
BAF155WT and MCF7-BAF155R1064K cells. BAF155WT and BAF155R1064K display
globulin G (IgG) was used as antibody control.
(B) ChIP-qPCR analysis of me-BAF155 binding to COL1A2 and GADD45A genes
(C) Relative mRNA levels of COL1A2 andGADD45A in MCF7-shBAF155, MCF7-B
b-Actin was used as an internal control.
(D) The me-BAF155 binding region on the COL1A2 gene and ChIP-qPCR analys
MCF7-shBAF155-GFP, MCF7-BAF155WT, and MCF7-BAF155R1064K cells.
(E) ChIP-qPCR analysis of me-BAF155, CARM1, BRG1, BRM, BAF53, and
BAF155R1064K cells. Normal rabbit IgG was used as control.
(F) ChIP-qPCR analysis of me-BAF155 association with the GADD45A gene in th
(G) ChIP-qPCR analysis of the association of me-BAF155, CARM1, BRG1, BRM
BAF155R1064K cells.
Quantitative data are presented as averages ± SD. Student’s t test was used formulated in the lung as expected (Minn et al., 2005). Time-
course analysis of the two cohorts revealed significant
differences in lung colonization. BAF155WT-expressing but not
BAF155R1064K-expressing cells showed colonization and tumor
outgrowth in lung (Figure 7D). Thus, BAF155 methylation is posi-
tively linked to lung metastasis.
To gain further insight into the mechanism by which
BAF155 methylation regulates MDA-MB-231 metastasis,
we employed the tumor metastasis RT2 profiler PCR array
(SABiosciences), containing 84 genes involved in metastasis, to
compare the mRNA expression profiles between MDA-MB-
231-BAF155R1064K and MDA-MB-231-BAF155WT (Figure 7E). If
more than 2-fold expression difference was seen between
the two cell lines, the corresponding genes are marked green
or red (Figure 7E) and are listed in Figure 7F. Two metastasis
repressor genes, CDH11 and KISS1R, were upregulated,
and six metastasis-promoting genes, CCL7, CDH6, COL4A2,
CXCL12, MMP13, and MYCL1, were downregulated in MDA-
MB-231-BAF155R1064K cells compared with BAF155WT cells.
Four genes were selected for validation using real-time PCR.
Indeed, KISS1R and CDH11 were expressed at higher levels in
MDA-MB-231-BAF155R1064K cells, whereas CCL7 and COL4A2
were expressed at higher levels in MDA-MB-231-BAF155WT
cells (Figure 7G). We further systematically compared the
differential gene expression of MDA-MB-231-BAF155WT
and -BAF155R1064K using Affymetrix microarrays. Over 700
genes were differentially expressed in two cell lines (p < 0.05);
322 and 411 genes were upregulated and downregulated,
respectively (Figure S7A). Among other differential expressed
genes identified (Table S3), the metastasis genes COL4A2
and TIMP3 (Figure 7F) and c-MYC pathway gene CDCA7 (Fig-
ure 5C) were expressed at higher levels in BAF155WT cells than
inBAF155R1064K cells. Geneontology pathway analyses revealed
that themajor differentially expressed genes fall in the categories
of cellular movement, cellular organization, cell proliferation,
and migration (Figure S7B). Moreover, despite the different cell
lines used to study gene expression andDNAbinding differences
between WT BAF155 and BAF155R1064K, one-fourth of the
differentially expressed genes identified by microarrays in
MDA-MB-231 cells overlap with differentially bound genomic
regions identified by ChIP-seq in MCF7 cells (Figure S7C). These
results suggest that BAF155 methylation regulates important
pathways involved in cancer progression, including cell move-
ment and migration.yc Pathway
NDRG1 genes was analyzed using ChIP-quantitative PCR (qPCR) in MCF7-
ed similar binding to the positive control CDH1 gene. Normal rabbit immuno-
.
AF155WT, and MCF7-BAF155R1064K cells were determined by real-time qPCR.
is of BAF155 association with the COL1A2 gene in MCF7, MCF7 CARM1 KO,
SNF5 association with the COL1A2 gene in MCF7-BAF155WT and MCF7-
e indicated cells.
, BAF53, and SNF5 with the GADD45A gene in MCF7-BAF155WT and MCF7-
statistical analysis. **p < 0.01. See also Figure S5.
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One important finding above is that knocking down endogenous
CARM1 by 90% is insufficient to mimic the biological effects of
complete CARM1 KO. This echoes the in vivo mouse model
where reducing CARM1 to 25% of endogenous level still sus-
tains normal development (Kim et al., 2010). Consistent with
this, CARM1 KO decreased cell and tumor growth in vitro and
in vivo, in contrast to little in vivo growth effect of CARM1
shRNA-mediated knockdown in MCF7 (Al-Dhaheri et al., 2011).
While CARM1 knockdown may selectively affect methylation of
some substrates but not others, our findings underscore the
importance of using complete KOs when studying the biological
functions of enzymes.
Although engineered ZFNs have been used for genome editing
in diverse model organisms, allele engineering in somatic cell
genetics has not been widely applied for determining enzyme
functions. KO efficiency by ZFNs varies among cancer cell lines
and depends on transfection efficiency and the multiplicity of the
targeted chromosome. For example, the CARM1 disruption fre-
quency reached 10% of alleles in diploid breast cancer cell line
CAL51 (data not shown), compared with 1.3% in MCF7 cells
where CARM1-bearing chromosome 19 is triplicated. In fact,
one-time transient transfection of a plasmid encoding the
CARM1 ZFN in MCF7 cells only disrupted CARM1 biallelically,
as confirmed by sequencing of genomic DNA. In agreement
with a report that sequential ZFN transfection of biallelically dis-
rupted clones resulted in triple locus KO at frequency of 1% (Liu
et al., 2010), limiting dilution and genotyping without antibiotic
selection yielded two MCF7 clones (out of 159) in which
CARM1 was disrupted triallelically (Figure 1E). Despite low KO
frequency in some cases, ZFN-mediated KO of genes like
CARM1 in cancer cell lines provides unprecedented opportu-
nities for cancer-relevant substrate discovery since, for example,
MEFs lack or express many CARM1 substrates at lower level
than CARM1 null cancer cell lines. Identifying cancer-relevant
substrates for CARM1 is essential for elucidating its functions
in cancer, as exemplified by BAF155.
SWI/SNF is a multisubunit chromatin-remodeling complex
that has been strongly implicated in cancer development due
to aberrant expression and mutation of its subunits in many
tumor types (Weissman and Knudsen, 2009). Accompanying
the SWI/SNF ATPase subunits (e.g., BRG1) are 9–12 BAF
proteins, including core and accessory subunits. The core
subunits, BAF155, BAF170, and SNF5 (also referred to as
SMARCB1, BAF47, or SNF5/INI1), were defined on the basis
of their ability to restore efficient nucleosome remodeling
in vitro (Phelan et al., 1999). Recent whole genome sequencing
of human tumors revealed that SWI/SNF subunits are mutated
in >20% of human malignancies (Kadoch et al., 2013). ForFigure 6. BAF155 Methylation Correlates with Human Breast Cancer P
(A–C) Immunohistochemical staining of me-BAF155 in representative normal bre
node metastasis specimens (C) on the US Biomax BR723 TMA. Brown staining
(D) The percentage of me-BAF155-positive staining in normal, TAN, benign, mal
(E) Kaplan-Meier curves depicting the probability of recurrence-free survival in br
(F) Kaplan-Meier curves for cumulative hazard (Cum Hazard).
(G) The recurrence hazard for breast cancer patients stratified by me-BAF155 st
See also Figure S6.example, SNF5 behaves as a bona fide tumor suppressor
gene (Roberts et al., 2002). Conflicting evidence suggests
that BAF155 may serve as tumor suppressor or oncogene
in a tumor-type-specific manner. BAF155 was initially impli-
cated as a tumor suppressor because of its residency in chro-
mosome 3p21.31, a region frequently deleted in lung and
other adenocarcinomas (Zabarovsky et al., 2002). Coincidently,
BAF155 expression is deficient in two ovarian cancer cell
lines, SKOV3 and SNUC2B (DelBove et al., 2011). However,
mounting evidence supports that, for at least some tumor
types, BAF155 might enhance tumor development. BAF155
expression is markedly induced in prostate cancer (Lapointe
et al., 2004), cervical intraepithelial neoplasia (Shadeo et al.,
2008), and colon cancer (Andersen et al., 2009). Elevated
BAF155 expression was correlated with poor prognosis and
recurrence in colon cancer (Andersen et al., 2009). The varied
BAF155 expression in distinct tumor types suggests that aber-
rant BAF155 levels may contribute to tumor initiation and pro-
gression in a context-dependent manner.
We report here that BAF155 is elevated in human breast
tumors and that increased methylation of BAF155 is associated
with poor survival, implicating BAF155 as an independent prog-
nosis biomarker. Individual ChIP experiments showed that some
genomic sites seem to bind BAF155 independently of BRG1.
Further ChIP-seq to improve signal/noise ratios and mapping
of genomic sites using anti-me-BAF155 and BRG1 antibodies
will more fully test BRG1-independent binding of BAF155 to
chromatin sites. Nonetheless, our results support that methyl-
ated BAF155 might have functions independent from the full
SWI/SNF complex, which agrees with earlier reports that individ-
ual SWI/SNF subunits confer oncogenic functions independently
of the entire complex (Park et al., 2002). For example, BAF53
formed a distinct complex with c-Myc cofactors, including
histone acetyltransferases to enhance c-Myc’s oncogenic trans-
formation activity (Park et al., 2002). It remains unknown whether
me-BAF155 and SNF5 form complexes distinct fromSWI/SNF at
genomic loci specific for me-BAF155, including c-Myc pathway
gene loci.
The c-Myc pathway deregulation is a common feature of
human tumorigenesis. The Myc oncoprotein provides selective
advantages to cancer cells by promoting proliferation, cell sur-
vival, genetic instability, and differentiation blockage, which
all contribute to metastasis. This study reveals that methylated
BAF155 is specifically recruited to c-Myc pathway genes,
some of which are direct c-Myc targets (e.g., GADD45A) and
some of which are not (e.g., COL1A2). COL1A2 produces a
component of type I collagen, the pro-a2 (I) chain, involved in in-
flammatory response pathways. COL1A2 was among a ‘‘meta-
signature’’ associated with breast cancer prognosis (Urquidi
and Goodison, 2007). GADD45A (DNA damage-induciblerogression, Malignancy, and Recurrence-Free Survival
ast (A), benign breast tumors (B), and malignant breast tumors including lymph
denotes me-BAF155 immunoreactivity. Scale bar = 200 mm.
ignant, and metastatic samples on the BR723 TMA.
east cancer patients stratified by me-BAF155 IHC positivity in primary tumors.
aining positivity using a Cox proportional hazards model.
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cellular responses to various stress conditions, including geno-
toxic and oncogenic stresses. Depending on the oncogenic
stress, GADD45A could function as promoter or suppressor for
breast cancer (Tront et al., 2010). GADD45A promotes tumor
vascularization and growth of Myc-driven breast cancer via
negative regulation of MMP10 (Tront et al., 2010).
Recently, ‘‘poor prognosis’’ gene expression signatures in
cancer, particularly in breast cancer, were found to reflect the
activity of the c-Myc oncoprotein, which in turn regulates tumor
metastasis through regulation of metastasis-relevant target
genes and/or globally altering the epigenomic landscape of
cancer cells (Wolfer et al., 2010). BAF155 methylation affects
expression of a number of genes involved in metastasis. Inter-
estingly, another study using the MDA-MB-231 cell line model
showed that c-Myc knockdown had modest effects on primary
tumor growth, whereas metastatic behavior and distant lung
metastasis were greatly inhibited (Wolfer et al., 2010). This
study suggests that c-Myc is essential for maintaining an inva-
sive and migratory state of the highly metastatic MDA-MB-231
cells. Future studies will determine whether BAF155-methyl-
ation-sensitive metastatic genes are directly regulated by
c-Myc. Given that 10%–15% of genomic loci in mammals are
bound by c-Myc (Zeller et al., 2006), it is plausible that c-Myc
affects metastasis-relevant gene expression via direct tran-
scriptional regulation mechanism or via global alteration of
chromatin structure of cancer cells, thus promoting the meta-
static phenotype.
EXPERIMENTAL PROCEDURES
Generation of CARM1 KO Cells
Cells were transiently transfected with plasmids encoding the indicated ZFN
pairs using lipofectamine 2000 (Invitrogen) for 72 hr. Single-cell clones were
isolated by limiting dilution of the ZFN-treated pool. The whole cell lysate of
each clone was collected and CARM1 levels were detected by western blot.
To analyze genomic DNA sequences of each positive clone, the target
locus was first amplified by PCR using primers CARM1-ZFN-sense: 50-
ACAGCCTGCCTTCTCAGG-30, anti-sense: 50-TGCACAGCAATGGCAAGT-30.
Then the PCR product was cloned into pCR4-TOPO vector. For each cell
line, plasmid DNAs from 50 bacterial colonies were sequenced.
Animal Models
All animal work was performed in accordance with protocols approved by
Research Animal Resource Center of University of Wisconsin-Madison. Athy-
mic nude mice at 5–6 weeks old were used for xenograft experiments (Harlan).
Information for the animal experiments is presented in the Supplemental
Experimental Procedures.Figure 7. BAF155 Methylation Promotes Breast Cancer Cell Migration
(A) Generation of anMDA-MB-231 cell derivative with endogenous BAF155 silenc
in this MDA-MB-231-shBAF155 cell background. Total BAF155 and me-BAF155
(B) The (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide assays
BAF155WT, or BAF155R1064K.
(C) Transwell assays measuring the migration ability of cell lines in (B).
(D) Bioluminescence images of colonized and metastatic MDA-MB-231-shBAF1
nude mice at the indicated times following tumor introduction through tail vein in
(E) Scatter plot of mRNA levels for 84 metastasis-implicated genes analyzed by
circles mark genes that are differentially expressedR2-fold between MDA-MB-
(F) List of >2-fold differentially expressed genes in (E). Positive fold change repre
(G) Real-time qPCR analyses of KISS1R,CDH11,CCL7, andCOL4A2mRNA level
b-Actin was used as an internal control.
See also Figure S7 and Table S3.Human Primary Tumor Samples
Breast cancer TMAs constructed by UW Carbone Cancer Center include tu-
mors from372 individual subjectswith Stage I to Stage III breast cancer treated
at the UWCarboneCancer Center from 1999 to 2007. TheUWHealth Sciences
Institutional Review Board approved the TMA creation and waived institutional
review board approval for future use of the TMA and coded data set.
In Vitro Methylation Assay
In vitro methylation assay was performed as previously described (Wang et al.,
2013).
ChIP-seq Analysis
For experimental details, please refer to the Supplemental Experimental
Procedures.
TMAs of Human Breast Tumors
TMAs constructed by UW Carbone Cancer Center include tumors from 372
individual subjects with Stage I to Stage III breast cancer treated from 1999
to 2007. The experimental details and statistical analyses are described in
Supplemental Experimental Procedures.
ACCESSION NUMBERS
The ChIP-seq data are available at the Gene Expression Omnibus under the
accession number GSE52964.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.12.007.
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